Novavax (NVAX) is expected to provide data this week for the Phase 1/2 flu study. The only problem is that the results were originally expected by the end of 2017.
Novavax CEO Stanley Erck made the following statement on the Q3'17 earnings call:
When the company does report the data on the NanoFlu vaccine, investors need to pay attention to the meaningful milestones provides by management. Watch the pre-BLA status shift into 2019 and don't expect any FDA approval before 2020, if ever.
The flu vaccine is in demand now, but naturally Novavax has no product inline for approval any time soon. The stock though could rally on any positive spin by the company. Be careful holding the stock after the rally.
Disclosure: No position. Please review the disclaimer page for more details.